BiotechTube

olmesartan

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vascular Function

Conditions

Vascular Function, Exercise Training

Trial Timeline

Dec 1, 2009 → Dec 1, 2011

NCT ID
NCT01053026

About olmesartan

olmesartan is a pre-clinical stage product being developed by Daiichi Sankyo for Vascular Function. The current trial status is completed. This product is registered under clinical trial identifier NCT01053026. Target conditions include Vascular Function, Exercise Training.

What happened to similar drugs?

20 of 20 similar drugs in Vascular Function were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅donepezil hydrochloride (Aricept)EisaiApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01053026Pre-clinicalCompleted
NCT00098137Phase 3Completed

Competing Products

20 competing products in Vascular Function

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
LexiscanAstellas PharmaPhase 2
35
YM872 (zonampanel)Astellas PharmaPhase 2
35
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35